Oral cholestyramine formulation and use thereof

An oral dosage form comprising:

• a) a plurality of pellets, each pellet comprising at least 70% w/w cholestyramine and
• i. a combination of at least 6% w/w of a vinylpyrrolidone-based polymer and at least 2% w/w of an acrylate copolymer;
• or
• ii. a combination of at least 5% w/w of a vinvlpyrrolidone-based polymer and at least 3% w/w of an acrylate copolymer;
• or
• iii. a combination of at least 6% w/w of a vinylpyrrolidone-based polymer, at least 1% w/w of an acrylate copolymer and at least 10% w/w microcrystalline cellulose;
• b) a diffusion-controlled inner coating surrounding each pellet;
• and
• c) an enteric outer coating;
• wherein the oral dosage form exhibits less than about 30% sequestration of cholic acid, chenodeoxycholic acid, and deoxycholic acid after 2 hours in small intestinal incubations (“SI-2”) as measured in a Simulator of the Human Intestinal Microbial Ecosystem (SHIME) model.